Skip to content

Evaluation of the therapeutic efficacy of modified irrigating percutaneous ethanol injection combined with microwave ablation for treatment of symptomatic predominantly cystic benign thyroid nodules

Evaluation of the therapeutic efficacy of modified irrigating percutaneous ethanol injection combined with microwave ablation for treatment of symptomatic predominantly cystic benign thyroid nodules

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044956
Enrollment
Unknown
Registered
2021-04-03
Start date
2015-04-01
Completion date
Unknown
Last updated
2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thyroid cyst and solid nodules

Interventions

Case series:modified irrigating percutaneous ethanol injection combined with microwave ablation

Sponsors

Beijing Friendship Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Symptomatic thyroid cysts or mainly cystic nodules on ultrasound (cystic component>50%); 2. Occurrence of compressive symptoms, such as neck pain or discomfort, difficulty in swallowing or breathing; 3. Cytological results were benign after at least twice fine-needle aspiration biopsies within 3 months (Bethesda class II)[23] , in the meanwhile, ultrasound patterns came out with very low suspicion of malignancy; 4. Unwillingness to undergo surgery treatment or poor surgery tolerance due to clinical conditions or aesthetic needs; 5. Patients who were anxious about esthetic problems or malignant change; 6. Recurrence of symptomatic cystic thyroid nodules after hemi-thyroidectomy; 7. Maximum diameter greater than 2 cm and the volume kept increasing.

Exclusion criteria

Exclusion criteria: 1. Biopsy evidence showed malignancy; 2. Critical positions which were too close to vessels, trachea, and esophagus or nerves that cannot be isolated effectively; 3. Pregnancy; 4. Patients with severe cardiopulmonary disease, liver diseases or renal failure that cannot tolerate treatment; 5. Coagulation dysfunction, severe bleeding tendency.

Design outcomes

Primary

MeasureTime frame
volume reduce ratio;

Countries

China

Contacts

Public ContactLinxue Qian

Beijing Friendship Hospital, Capital Medical University

qianlinxue2002@163.com+86 13311100999

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026